A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in Low Risk (LR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs): A Report from Children's Oncology Group Study AALL1331

Standard treatment of children and AYAs with LR first relapse of B-ALL [LR defined as bone marrow with or without extramedullary (BM±EM) relapse ≥36 months or isolated EM (IEM) relapse ≥18 months from initial diagnosis, and low (

Saved in:
Bibliographic Details
Published in:Blood 2021-11, Vol.138 (Supplement 1), p.363-363
Main Authors: Brown, Patrick A., Ji, Lingyun, Xu, Xinxin, Devidas, Meenakshi, Hogan, Laura, Bhatla, Teena, Borowitz, Michael, Raetz, Elizabeth A., Gore, Lia, Whitlock, James A., Hunger, Stephen P., Loh, Mignon L.
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Standard treatment of children and AYAs with LR first relapse of B-ALL [LR defined as bone marrow with or without extramedullary (BM±EM) relapse ≥36 months or isolated EM (IEM) relapse ≥18 months from initial diagnosis, and low (
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2021-147946